Board of Directors

Peter Benson (born 1955) is Chairman and co-founder of Sunstone Capital Life Science Ventures and chairman of Alligator Bioscience AB, which is listed on Nasdaq Stockholm. Peter Benson has extensive experience from the Life Science sector as an investor, board member and in senior management positions, including in several listed companies. Peter Benson was vice chairman of Zealand Pharma during its IPO and has previously inter alia been Head of Life Science Ventures at Vækstfonden (the Danish Growth Fund), President of Hospital Care and Senior Vice President at Pharmacia AB as well as Executive Vice President Marketing & Sales at Kabi Pharmacia Parenterals.

Graduate in business administration from Lund University, Sweden. MA in Economics from the University of California, US.

Chairman of Alligator Bioscience AB (publ), Ascelia Incentive AB and Sunstone LSV Partners Holding ApS. Board member Arcoma Aktiebolag and Sunstone Capital A/S (and subsidiaries within the Sunstone Capital A/S sphere).

-

Independent in relation to the Company and its management, but not in relation to major shareholders. Managing Partner of Sunstone Life Science Venture A/S and board member of CMC SPV of 3 April 2017 AB.

Lauren Barnes (born 1974) is Senior Vice President, Market Access for Blueprint Medicines (listed on Nasdaq), a commercial stage Boston based precision medicine company focusing on genomically defined cancers, rare diseases and cancer immunotherapy. Lauren Barnes has extensive expertise and experience in pricing, market access, pre-commercialization and managed markets in particular for the US market. She has been involved in launch planning of more than 50 drugs, devices and diagnostics during her career. Prior to her current role Lauren was Vice President at Vertex Pharmaceuticals, SVP Avalere Health and led their Reimbursement & Commercialization practice and has also held various roles at Amgen and the agency that runs the United States Medicare Program, the Centers for Medicare and Medicaid Services.

MHS in Public Health from the Johns Hopkins School of Public Health and BA in Public Health from the Johns Hopkins University.

Chair of the National Board of the Cancer Support Community.

-

Independent in relation to the Company and its management and in relation to major shareholders.

Bo Jesper Hansen (born 1958) has extensive experience from orphan drug research and development, international marketing and business development. Bo Jesper Hansen is and has previously been chairman and member of the board of directors in a number of biotech and pharma companies, including executive chairman of Swedish Orphan Biovitrum AB (publ), Topotarget A/S (publ) and Karolinska Development AB (publ) and chairman of Ablynx nv (publ).

M.D. and Ph.D. from University of Copenhagen, Denmark.

Chairman Karo Pharma AB, Innoventa Medica ApS and Laborie Inc. Board member of Azanta A/S. Vice-chairman of Orphazyme ApS.

350,019 shares in Ascelia Pharma AB.

Independent in relation to the Company and its management and in relation to major shareholders.

Hans Maier (born 1955) is Managing Partner and co-founder of the Healthcare and Life Science Strategy and Transaction Advisor BGM Associates GmbH, Berlin Germany. In his career as a biopharma executive, Hans Maier has held executive positions within Schering AG and Bayer AG, inter alia as Managing Director of Schering’s subsidiaries in Japan and Korea, Managing Director of Schering Dermatology, Head of Corporate Strategy and Business Development of Schering AG and President of the Global Business Unit Diagnostic Imaging in both Schering AG and Bayer AG. He also served on the Executive Committee of Bayer-Schering Pharma AG.

Ph.D.in Economics and Diploma in Political Science from Freie Universität Berlin, Germany.

President of the Board of Trustees of the German Heart Center Berlin, Chairman of the Advisory Board of the Fraunhofer Mevis Institute for Digital Medicine, Professor of International Strategic Management at Berlin School of Economics and Law.

20,000 shares in Ascelia Pharma AB.

Independent in relation to the company and its management and in relation to major shareholders.

Niels Mengel (born 1948) is Founding Partner, board member and CEO of Øresund-Healthcare Capital. Niels Mengel has extensive experience from the healthcare industry as an investor. Niels Mengel has previously inter alia been Executive Vice President at ISS World Services A/S and Director at PA Consulting Group.

M.B.A. from London Business School, England. M.Sc. in Macro Economy and Finance from University of Copenhagen, Denmark.

Board member of Dansk Aktionærforening. Board member of Better Finance (The European Federation of Investors and Financial Services Users), Black Swan Strategy A/S and Upstream Invest A/S. Board member and managing partner of Øresund-Healthcare Management A/S. Limited partner of Øresund-Healthcare Capital K/S. Partner of ØHM Exit I I/S and ØHM Exit II I/S. Member of management (executive) in Kibegeon ApS.

138,293 shares in Ascelia Pharma AB directly or through company. Niels Mengel has also, directly and indirectly, invested in Øresund-Healthcare that holds 2,020,490 shares in Ascelia Pharma AB. Through the agreements governing Niels Mengel’s investments in Øresund-Healthcare, Niels Mengel has a financial interest corresponding to approximately 50 per cent of the shares in Ascelia Pharma AB held by Øresund-Healthcare.

Independent in relation to the company and its management and in relation to major shareholders.

René Spogárd (born 1954) is chairman and investor in a number of companies including JEKA Fish A/S, Bollerup Jensen A/S and Flex Funding A/S. René Spogárd has extensive experience from investing in the healthcare sector and board positions in a public environment. René Spogárd has previously inter alia been owner and Managing Director at TNS Gallup A/S and Director at TNS plc (listed on London Stock Exchange).

H.D. in Marketing from Copenhagen Business School, Denmark.

Chairman of Ambrox Property Invest III A/S, Bollerup Jensen A/S, Bollerup Jensen Adhesives ApS, Bollerup Jensen Water Holding ApS, CMC SPV of 3 April 2017 AB, Cimbric A/S, Deltaq Portefølje Holding 104 ApS, Deltaq Portefølje Holding II ApS, Deltaq Portefølje Holding IV ApS, Deltaq Portefølje Holding VI ApS, Flex Funding A/S, Jeka Fish A/S, Jeka Fish Holding ApS, Jeka Fish Holding 2 ApS, Jysk Industri Holding A/S and Preservation Technologies I/S. Deputy chairman of Nordisk Krabbe Kompagni A/S. Board member of Ambrox Capital A/S, Ambrox Korsør A/S, Bollerup Jensen Adhesives Holding ApS, Bollerup Jensen Water ApS, Bollerup Jensen Wood ApS and Flex Funding Fintech ApS. Member of management (executive) and partner of Dadephi ApS, René Spogárds amilieanpartsselskab, Spogárd Holding ApS, Spogárd Invest ApS and Spogárd Invest 3 ApS.

1,010,203 shares in Ascelia Pharma AB indirectly through company.

Independent in relation to the Company and its management and in relation to major shareholders.

Helena Wennerström (born 1965) is Chief Financial Officer at ViaCon Group. Previously she was Executive Vice President and Chief Financial Officer of Bulten AB (publ). Earlier she also had finance roles at Digitalfabriken and Topcon.

Master of Science in Business Administration and Economics from Örebro University.

Deputy board member in TVM Consulting i Göteborg AB and deputy board member in ViaCon Group AB (publ).

18,000 shares in Ascelia Pharma AB.

Independent in relation to the Company and its management, and in relation to major shareholders.